Abstracts

ART INITIATED AT HIGH CD4 NADIR DOES NOT NORMALIZE CSF MARKERS OF IMMUNE ACTIVATION

HIV infects cells in the central nervous system (CNS), mainly microglia and perivascular macrophages, and induces a chronic intrathecal immune activation. Similar to its effect outside the CNS, antiretroviral treatment (ART) substantially decreases CNS inflammation and CD4+ T-cell trafficking through the cerebrospinal fluid (CSF) is often reduced to near normal levels. Yet, CSF levels of…

USE OF D/C/F/TAF WITH NEUROLOGIC/PSYCHIATRIC COMORBIDITIES: AMBER SUBGROUP ANALYSIS

Patients with human immunodeficiency virus (HIV)–1 and neurologic or psychiatric comorbidities (NPCs) may face challenges with HIV-1 care. The phase 3 AMBER trial (ClinicalTrials.gov: NCT02431247) enrolled treatment-naïve, HIV-1–infected adults who were randomized 1:1 to receive once-daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10mg or control (D/C+F/tenofovir disoproxil fumarate). Here we report a subgroup analysis evaluating efficacy/safety in those…

INTEGRASE INHIBITOR START OR SWITCH IMPACTS LEARNING IN WOMEN WITH HIV

In recent years, the integrase strand transfer inhibitor (INSTI) class of antiretroviral therapy (ART) has become an integral component of HIV treatment. Despite concerns regarding neuropsychiatric adverse events there are limited data on cognitive side effects, particularly in women with HIV (WWH). WWH enrolled in the Women’s Interagency HIV Study (WIHS), who started or switched to INSTI-based…